View Older Stories View More Recent Stories

Jan 9, 2023 05:06AM CymaBay Therapeutics (CBAY) Collaborates with Kaken Over Seladelpar in Japan for Primary Biliary Cholangitis
Jan 8, 2023 12:00PM CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis
Nov 14, 2022 04:06PM CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update
Nov 7, 2022 04:05PM CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022
Nov 4, 2022 08:00AM CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
Nov 3, 2022 08:00AM CymaBay Therapeutics to Present at Upcoming Investment Conferences
Nov 1, 2022 08:03AM CymaBay Therapeutics (CBAY) Appoints Charles McWherter as Chief Scientific Officer
Nov 1, 2022 08:01AM CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development
Oct 3, 2022 08:00AM CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
Sep 14, 2022 08:00AM CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
Sep 6, 2022 08:02AM CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 24, 2022 08:00AM CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
Aug 11, 2022 04:05PM CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update
Aug 4, 2022 04:05PM CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022
Aug 1, 2022 08:00AM CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis
Jun 22, 2022 08:07AM CymaBay Therapeutics (CBAY) Presents Positive PBC Data at the International Liver Congress 2022
Jun 22, 2022 08:00AM CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
Jun 8, 2022 08:00AM CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022
May 23, 2022 08:00AM CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
May 12, 2022 04:06PM CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022 08:00AM CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022
May 5, 2022 04:01PM CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022
Apr 4, 2022 08:02AM CymaBay Therapeutics (CBAY) Reports Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis
Apr 4, 2022 08:00AM CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis
Mar 17, 2022 04:25PM CymaBay Therapeutics (CBAY) Appoints Eric Lefebvre to its Board
Mar 17, 2022 04:25PM CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors
Mar 17, 2022 04:06PM CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update
Mar 10, 2022 04:05PM CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022
Feb 10, 2022 08:00AM CymaBay Therapeutics to Present at Upcoming Investor Conferences
Nov 15, 2021 08:00AM CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC
Nov 11, 2021 08:00AM CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
Nov 10, 2021 04:06PM CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update
Nov 4, 2021 08:00AM CymaBay Therapeutics to Present at Upcoming Investor Conferences
Nov 3, 2021 04:05PM CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
Oct 1, 2021 08:00AM CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021
Aug 30, 2021 08:00AM CymaBay Therapeutics to Present at Upcoming Investor Conferences
Aug 12, 2021 04:06PM CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
Aug 5, 2021 04:01PM CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
Aug 2, 2021 08:00AM CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth
Jun 21, 2021 08:00AM CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021
Jun 14, 2021 08:00AM CymaBay Therapeutics to Present at Upcoming Investor Conferences
Jun 9, 2021 08:00AM CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021
May 18, 2021 08:00AM CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2021 04:06PM CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 08:00AM CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical Officer
May 11, 2021 08:00AM CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2021 08:00AM CymaBay Names Lewis Stuart Chief Commercial Officer
Sep 22, 2020 07:00AM Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
Jul 23, 2020 09:31AM Pre-Open Movers 07/23: (CBAY) (NTGR) (HZO) Higher; (LLNW) (ALGN) (MSFT) Lower (more...)
May 15, 2015 10:13AM CymaBay Therapeutics Inc. (Nasdaq: CBAY) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories View Older Stories